Aurobindo Pharma Ltd.

Dec 03, 2019 18:23 Source: BSE

Aurobindo Pharma - Disclosure Of Related Party Transactions For The Half Year Ended 30Th September 2019.

Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith disclosure of Related Party Transactions on a consolidated basis, in the format specified in the accounting standards for the half year ended 30th September 2019.

Dec 02, 2019 17:27 Source: BSE

Aurobindo Pharma - Disclosure of Voting results of Court Convened Meeting (Regulation 44(3) of SEBI (LODR) Regulations, 2015)

Aurobindo Pharma Ltd has informed BSE regarding the details of Voting results of Court Convened Meeting, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here

Dec 02, 2019 15:43 Source: BSE

Aurobindo Pharma - Voting Results And Scrutinizers Report Of NCLT Convened Meetings Of The Equity Shareholders And Unsecured Creditors Of Aurobindo Pharma Limited (The 'Company')

Pursuant to Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, in relation to the Tribunal convened meetings of Equity Shareholders and Unsecured Creditors of the Company convened on November 30, 2019, at 03:30 PM & 02:00 PM respectively, pursuant to the Order of the Hon''ble National Company Law Tribunal, Bench at Hyderabad, we submit the following: (a) Voting Results and Scrutinizer''s Report on the meeting of the Equity Shareholders. (b) Scrutinizer''s Report on the meeting of the Unsecured Creditors. We further wish to inform that as per the reports of Scrutinizers, the Equity Shareholders and Unsecured Creditors of the Company, at their respective meetings held on November 30, 2019 have approved the proposed Scheme of Amalgamation with the requisite majority. The above documents have been made available on the Company''''s website www.aurobindo.com.

Nov 30, 2019 21:46 Source: BSE

Aurobindo Pharma - Outcome Of NCLT Convened Meeting Of The Equity Shareholders Of Aurobindo Pharma Limited (The 'Company') And Disclosures Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, in relation to the Tribunal convened meeting of Equity Shareholders of the Company convened on November 30, 2019, at 03:30 PM, pursuant to the Order of the Hon''ble National Company Law Tribunal, Bench at Hyderabad, we submit Summary of proceedings of the meeting of the Equity shareholders.

Nov 28, 2019 18:05 Source: BSE

Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Acquisition

This is to inform you that Auro Vaccines LLC, 100% subsidiary of Aurobindo Pharma USA Inc., USA, which in turn is 100% subsidiary of the Company, has entered into a definitive agreement to acquire certain business assets from Profectus BioSciences Inc., USA., a clinical-stage vaccine development company. The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as ''Annexure A''.

Nov 28, 2019 11:04 Source: NSE

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

Nov 28, 2019 10:30 Source: BSE

Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Please refer to our letter dated November 8, 2019 wherein we have intimated the schedule of Investors/Analysts call on November 13, 2019. We are attaching herewith the Transcript of the analyst / investor call on the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2019 and the same is being uploaded on the website of the Company and is available in the following web link: https://www.aurobindo.com/investors/results-reports-presentations/conference-call-transcripts/

Nov 16, 2019 16:59 Source: BSE

Aurobindo Pharma - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 16, 2019 for K. Nityananda Reddy

Nov 13, 2019 9:35 Source: NSE

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange that the Company has fixed Record Date as November 23, 2019 for the purpose of payment of Interim Dividend.

Nov 13, 2019 9:35 Source: NSE

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on November 12, 2019, has inter alia, transacted the following businesses: 1. Approved an Interim Dividend @ 125% i.e Rs.1.25 (Rupee one and paise twenty five) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2019-20.